Exelixis, Inc. (EXEL)
54.44
-0.82
(-1.48%)
USD |
NASDAQ |
Aug 28, 16:00
54.42
-0.02
(-0.04%)
After-Hours: 20:00
Exelixis Cash from Operations (Quarterly) : 307.74M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 307.74M |
| March 31, 2026 | 251.84M |
| December 31, 2025 | 333.52M |
| September 30, 2025 | 290.32M |
| June 30, 2025 | 48.99M |
| March 31, 2025 | 211.44M |
| December 31, 2024 | 240.26M |
| September 30, 2024 | 271.34M |
| June 30, 2024 | 119.55M |
| March 31, 2024 | 68.82M |
| December 31, 2023 | 10.57M |
| September 30, 2023 | 117.37M |
| June 30, 2023 | 120.98M |
| March 31, 2023 | 84.41M |
| December 31, 2022 | 73.69M |
| September 30, 2022 | 110.07M |
| June 30, 2022 | 31.13M |
| March 31, 2022 | 147.72M |
| December 31, 2021 | 96.45M |
| September 30, 2021 | 83.31M |
| June 30, 2021 | 181.50M |
| March 31, 2021 | 39.54M |
| December 31, 2020 | 33.29M |
| September 30, 2020 | 17.94M |
| June 30, 2020 | 101.68M |
| Date | Value |
|---|---|
| March 31, 2020 | 56.07M |
| December 31, 2019 | 158.02M |
| September 30, 2019 | 75.61M |
| June 30, 2019 | 131.73M |
| March 31, 2019 | 161.59M |
| December 31, 2018 | 104.59M |
| September 30, 2018 | 164.55M |
| June 30, 2018 | 74.77M |
| March 31, 2018 | 71.81M |
| December 31, 2017 | 53.35M |
| September 30, 2017 | 37.86M |
| June 30, 2017 | 5.535M |
| March 31, 2017 | 68.86M |
| December 31, 2016 | 83.71M |
| September 30, 2016 | -8.494M |
| June 30, 2016 | -25.73M |
| March 31, 2016 | 156.81M |
| December 31, 2015 | -35.43M |
| September 30, 2015 | -34.23M |
| June 30, 2015 | -26.83M |
| March 31, 2015 | -45.09M |
| December 31, 2014 | -49.98M |
| September 30, 2014 | -58.01M |
| June 30, 2014 | -55.34M |
| March 31, 2014 | -72.09M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | 56.10M |
| Madrigal Pharmaceuticals, Inc. | 23.33M |
| United Therapeutics Corp. | 310.20M |
| AbbVie, Inc. | 3.436B |
| Tonix Pharmaceuticals Holding Corp. | -41.87M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 91.43M |
| Cash from Financing (Quarterly) | -343.88M |
| Free Cash Flow | 1.172B |
| Free Cash Flow Per Share (Quarterly) | 1.159 |
| Free Cash Flow to Equity (Quarterly) | 304.54M |
| Free Cash Flow to Firm (Quarterly) | 300.92M |
| Free Cash Flow Yield | 7.96% |